Trial Profile
Multi-centre platform study of Osimertinib in patients with advanced non-small cell lung cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2018
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ORCHARD
- Sponsors AstraZeneca
- 26 Oct 2018 New trial record